Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,047

Document Document Title
WO/2018/184115A1
Compounds comprising quinazolinone derivatives and methods of identification and use of imaging agents. The compounds have the general formula I: wherein R2 is selected from halogen, halosubstituted alkyl, alkyl, hydroxyl-alkyl, and amin...  
WO/2018/187158A1
The present application relates to an anti-endoglin antibody in combination with an anti-PD-1 antibody. The present application relates to an anti-endoglin antibody in combination with an anti-PD-L1 antibody. The present application rela...  
WO/2018/178936A1
The application is drawn to radiolabeled biomolecules and methods for radiolabeling biomolecules with radioactive halogen atoms that minimizes loss of the radioactive halogen due to dehalogenation in vivo, preserves the biological activi...  
WO/2018/183906A1
The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula (I) or a pharmaceutically acceptable salt thereof...  
WO/2018/183232A2
Peptides conjugated to therapeutic, imaging, or diagnostic moieties to form peptide conjugates for use in treating, imaging, and/or diagnosing a cancer, such as breast cancer, in a subject in need of such treatment are disclosed.  
WO/2018/181877A1
The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-...  
WO/2018/178923A1
This invention relates to a bioconjugate comprising a chelating agent capable of containing a radionuclide linked to Substance P for use as an imaging agent in a method for detection of increased availability of NK-1 receptors for diagno...  
WO/2018/174721A2
The present invention discloses Indicator fluids, reference indicator fluid, and usage thereof, and systems and methods for assessing movement of molecular substances within, to or from a cerebrospinal fluid, brain or spinal cord compart...  
WO/2018/169440A1
The invention relates to the field of radiotherapyand, more specifically, to production of a radiopharmaceutical for treating preferably cancers. The method provided comprises the use of mono isotopic element Be-9 irradiated with quanta ...  
WO/2018/165752A1
The present description relates to a conjugated anti-interleukin-5 receptor α-subunit (IL-5Rα) compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear loca...  
WO/2018/169356A1
The present invention relates to a pigment-coupled mannosyl serum albumin complex and a lymph node-probing composition comprising the same. More particularly, when administered to mice, a pigment-coupled mannosyl serum albumin complex ca...  
WO/2018/168643A1
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...  
WO/2018/169942A1
A method for preparing 18F radiolabeled biomolecules and agents for 18F-PET imaging is disclosed herein. A perfluoroaryl-conjugated target tracer is synthesized and purified with temperature and solvent conditions that are mild for the t...  
WO/2018/164043A1
Provided is a labeled precursor compound represented by formula (2). (In the formula, S represents a substrate, L represents a C1-6 linear alkyl group which may contain an ether group, R1 and R2 each independently represent a C1-30 linea...  
WO/2018/165460A1
Novel methods of treating tumors, including neuroendocrine tumors (NET), such as a catecholamine-secreting tumor (CST), are disclosed. The methods include treating Cushing's syndrome in a Cushing's syndrome patient having a NET, such as ...  
WO/2018/164184A1
Disclosed is a compound selected from among aniline derivatives represented by formula (1) and naphthalene derivatives represented by formula (2), or a salt thereof. (In the formulae, each of R1 and R2 independently represents a hydrogen...  
WO/2018/160662A1
The inventors surprisingly found that neural stimulation caused the synthesis and degradation of proteins into peptides which were then secreted into the cell media within minutes of stimulation by a novel neural membrane bound proteasom...  
WO/2018/160544A1
An automated apparatus and method for producing a 68Ga radiopharmaceutical is provided. The apparatus can direct fluid flow through a radiopharmaceutical generator, a vessel in a temperature controlled reactor, and a solid phase extracti...  
WO/2018/160913A1
A method for preparing a radiolabeled pharmaceutical. The method comprises passing a mixture that includes a radiolabeled compound through a column that contains an ion exchange resin to retain the radiolabeled compound on the ion exchan...  
WO/2018/157696A1
Disclosed are an ATP1A1-targeting polypeptide and the use thereof. The motif of the ATP1A1-targeting polypeptide is SISSLTH, and 1-3 amino acids are optionally linked to the C-terminus and/or N-terminus of the motif. The ATP1A1-targeting...  
WO/2018/160553A1
Disclosed herein are reagents, compositions and methods for isolating and detecting rare cells such as circulating multiple myeloma cells as well as method of evaluating and treating patients suspected of having diseases of abnormal plas...  
WO/2018/154034A1
The invention relates to imaging, diagnostic, prognostic and therapy in the general field of nuclear medicine. Inventors herein describe new products for use for labelling, detecting, imaging, measuring, diagnosing, staging and/or monito...  
WO/2018/154470A1
The present disclosure relates to a process for the preparation of core-shell particles by the coacervation method encapsulating contrast agents for multimodal imaging. The process consists in: a.Providing a water in oil emulsion of a bi...  
WO/2018/153842A1
The present invention relates to the use of radium-223, particularly a pharmaceutically acceptable salt of radium-223, and combinations comprising radium-223, for the preparation of a medicament for the treatment or prophylaxis of a haem...  
WO/2018/153975A1
The present invention provides a method of combination therapy comprising administration of a tissue-targeting radiopharmaceutical and a DNA-repair inhibitor. The method may be used in the treatment of hyperplastic or neoplastic disease,...  
WO/2018/153966A1
The present invention relates to novel compounds useful for visualizing cell sen es c en ce in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particul...  
WO/2018/150326A1
Disclosed herein is a method of treatment involving the combination of an anti-OX40 antigen binding protein (e.g., an anti-OX40 agonist antibody) and/or radiotherapy, for use in treating a cancer. The cancer may include anti-PD-1 resista...  
WO/2018/148113A1
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditi...  
WO/2018/148224A1
Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), w...  
WO/2018/148509A1
Provided are methods of evaluating an ability of a therapeutic composition to modulate a dopaminergic activity in an organ of a mammalian subject having a dopaminergic disorder. Also provided are methods of assessing and monitoring the p...  
WO/2018/148476A1
Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.  
WO/2018/148209A1
This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.  
WO/2018/145206A1
The present application discloses methods of making anti-G-CSF antibodies, anti-G-CSF antibodies, methods of screening the activity of anti-G-CSF antibodies, pharmaceutical compositions of anti-G-CSF antibodies, kits containing anti-G-CS...  
WO/2018/141069A1
Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with th...  
WO/2018/143938A1
The present invention relates to monospecific antibodies against CXCR4 or binding fragments thereof, to the use of such anti-CXCR4 antibodies or binding fragments in treating diseases whose pathogenesis is related to activation of CXCR4,...  
WO/2018/141541A1
The invention concerns a compound having formula (I): wherein R1 represents a radioactive isotope of an element which radioactive isotope is detectable by positron emission tomography (PET) or wherein R1 represents any nonradioactive iso...  
WO/2018/138744A1
It is claimed the invention of a composition and a device to be used in medical therapy as a containment matrix in conformational intra-tissue beta brachytherapy. The composition is made so as to form a gel which can be injected intra-ti...  
WO/2018/138744A8
It is claimed the invention of a composition and a device to be used in medical therapy as a containment matrix in conformational intra-tissue beta brachytherapy. The composition is made so as to form a gel which can be injected intra-ti...  
WO/2018/138372A1
The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR...  
WO/2018/134430A1
The present invention relates to the use of radioimmunoconjugates for the treatment of bone marrow associated diseases, particularly AL-amyloidosis.  
WO/2018/136455A1
Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. Th...  
WO/2018/136669A3
Nonnatural peptides and their methods of use in human or non-human animal subject to cause an effect such as: neuroprotection, protecting against or lessening nerve impairment or damage, treating glaucoma, treating age-related macular de...  
WO/2018/132751A1
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrog...  
WO/2018/131911A1
The present invention provides a radioactive compound for contrasting malignant melanoma and use as a contrast medium using the same for PET contrast.  
WO/2018/129284A1
The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and...  
WO/2018/126280A1
The present invention provides a method of preventing damage to non-neoplastic cells i.e. healthy cells by irradiating with a low-dose radiation to the non-neoplastic cells, wherein the low-dose radiation is used to initiate a protective...  
WO/2018/126183A2
Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising th...  
WO/2018/116274A1
The invention is directed to a body comprising oxides of lanthanides, in particular holmium oxide (Ho2O3), which are supported on a sulphur containing carbon based particle and to a process for producing said body.  
WO/2018/115204A1
A peptide ligand specific for MT1 -MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at ...  
WO/2018/119313A1
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disord...  

Matches 1 - 50 out of 13,047